A New Cell Therapy Approach Advances Toward Clinical Testing in Synovial Sarcoma
Zelluna, a Norway-based biotechnology company, has announced the submission of a Clinical Trial Application (CTA) in the United Kingdom for…
Synovial Sarcoma Foundation Welcomes Julie Kramer as Community Engagement & Partnerships Manager
Current Patient to Drive Relationships and Support for the Synovial Sarcoma Community [Philadelphia, PA] – 12/12/25 – The Synovial Sarcoma…
Arizona Pioneers New Immune Therapy for Synovial Sarcoma Treatment
In a groundbreaking advancement in cancer treatment, a patient with synovial sarcoma in Arizona has become the first in the…
Revolutionary Insights Unveiled in Latest Synovial Sarcoma Research
A landmark study just published in Nature Communications finally pinpointed the exact “cell of origin” for synovial sarcoma — a rare, primitive…
2025 Connective Tissue Oncology Society
The Synovial Sarcoma Foundation is excited to share that we are on site this week at the 2025 Connective Tissue Oncology Society…
Rise in Early-Onset Cancers: More Diagnoses, Not Always More Disease
Not every detected cancer is clinically meaningful. For younger patients, especially, this can mean confronting a diagnosis that may never…
Dr. Theodore W. Laetsch, Synovial Sarcoma Foundation Board Member, Receives $1 Million Grant to Advance Rare Tumor Studies
The Synovial Sarcoma Foundation is pleased to highlight a significant milestone at the Children’s Hospital of Philadelphia (CHOP), where pediatric…
Innovative Approach Shows Promise Against Synovial Sarcoma Using Protein-Blocking Drugs
The Synovial Sarcoma Foundation is dedicated to supporting cutting-edge research that advances treatment options for this rare and aggressive cancer.…
New Market Insights Highlight Growth in Synovial Sarcoma Treatments
The Synovial Sarcoma Foundation is committed to staying informed on the latest research and developments in this rare and aggressive…